Showing results (1311-1320 of 2,470) with videos related to
Sort By:
Pageof 247
Cancer Treatment Reviews|October 24, 2019
Advances and challenges in precision medicine in salivary gland cancerGerben Lassche, Wim van Boxtel, Marjolijn J L Ligtenberg, et al.Cancer Treatment Reviews|May 16, 2021
Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approachesJames M Lonie, Andrew P Barbour, Riccardo DolcettiCancer Treatment Reviews|May 20, 2021
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backboneBengt Glimelius, Sebastian Stintzing, John Marshall, et al.Cancer Treatment Reviews|May 20, 2021
Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical dataPhilippe Barthélémy, Nathalie Rioux-Leclercq, Constance Thibault, et al.Cancer Treatment Reviews|August 21, 2021
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variantsMarina Macchini, Federico Centonze, Umberto Peretti, et al.Cancer Treatment Reviews|August 26, 2021
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysisMichela Giustozzi, Cecilia Becattini, Fausto Roila, et al.Cancer Treatment Reviews|August 26, 2021
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitorsDimitri Arangalage, Nils Degrauwe, Olivier Michielin, et al.Cancer Treatment Reviews|August 20, 2022
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?Giovanna Garufi, Luisa Carbognin, Concetta Arcanà, et al.Cancer Treatment Reviews|August 23, 2022
Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?Renata Colombo Bonadio, Paolo Tarantino, Laura Testa, et al.Cancer Treatment Reviews|August 23, 2022
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time biasMaria Kfoury, Marie Najean, Ariane Lappara, et al.Pageof 247